U.S. License Holder:
Genentech
Date of License:
June-02-2000
Last Update:
Nov-30-2023
FDA-Approved Indications
TNKase (tenecteplase) is a tissue plasminogen activator, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).